Medtrans Inc is categorized under Wheel Chairs Manufacturers in Los Angeles, CA and active since 2010.
Medtrans Inc was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Wheel Chairs Manufacturers business, which does work in the B2B market, and is classified as a Wheel Chairs Manufacturers, under code number 6219100 by the NAICS.
If you are seeking more information, feel free to contact Peter Avetisyan, Owner at the company’s single location by writing to 345 South Woods Avenue, Los Angeles, California CA 90022 or by phoning (323) 780-9500. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Medtrans Inc |
| Contact Person: | Peter Avetisyan, Owner |
| Address: | 345 South Woods Avenue, Los Angeles, California 90022 |
| Phone Number: | (323) 780-9500 |
| Website Address: | med-trans.net |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Wheel Chairs Manufacturers |
| SIC Code: | 3842 |
| NAICS Code: | 6219100 |
| Share This Business: |
Medtrans Inc was started in 2010 to provide professional Wheel Chairs Manufacturers under the SIC code 3842 and NAICS code 6219100. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Peter Avetisyan, Owner for inquiries that concern Medtrans Inc by calling the company number (323) 780-9500, as your correspondence is most welcome. Additionally, the physical location of the single location of Medtrans Inc can be found at the coordinates 34.03155,-118.15528 as well as the street address 345 South Woods Avenue in Los Angeles, California 90022.
For its online presence, you may visit Medtrans Inc’s website at med-trans.net and engage with its social media outlets through on Twitter and on Facebook.